Tagged with EDA

Coronavirus The CEOs and top executives, David Ricks, chairman and CEO, Eli Lilly & Co and IFPMA president, Severin Schwan, CEO, Roche, Paul Stoffels, chief scientific officer, Johnson & Johnson, David Loew, executive VP, Sanofi Pasteur and Rajeev Venkayya, president, Global Vaccines Business Unit, Takeda took part in a virtual press…

Czech Republic Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before being able to enter the market.   While the timelines are still outside the defined framework, the situation is much…

Czech Republic A cross-industry push for better and broader access to innovative treatments is underway in the Czech Republic. Ripe for reform is the country’s orphan drug legislation as no standard pathway for their assessment, pricing and reimbursement currently exists.   [For cancer treatment the country has been] quite successful in moving…

Romania Dominika Kovacs, country manager of Takeda Romania, shares her insights on the growing pipeline of the organisation and the anticipated launch of a state-of-art stem cell therapy. She highlights the organisational changes in the last year, and how they have been inducive to double-digit growth for Takeda. Additionally, she reveals…

UAE With nearly 240 years of history behind it, Takeda continues to position itself as a leading global R&D-driven biopharmaceutical organization. Dr Mahender Nayak, recently appointed area head of India, the CIS countries, Middle East, Turkey, and Africa (ICMEA), explains the company’s strategic presence in the region and outlines his strategy…

Belgium Joris Van Assche, managing director of the Belgian association for accessible medicines, Medaxes, highlights the need for a stronger policy to create a more positive environment for generic and biosimilar medicines. He also outlines the important role the off-patent sector plays in the long-term sustainability of Belgium’s universal healthcare system.…

Czech Republic Kieran Leahy, general manager of Takeda in the Czech Republic and Slovakia, recounts how he has led the transformation of Takeda into a specialty care organization at the local level, and his priorities to successfully integrate Shire along this journey. Leahy also breaks down the market access challenges in the…

Sweden Originally from Croatia, Vatroslav Mateljic was appointed as the general manager of Takeda Sweden in April 2019. Mateljic outlines how Takeda is integrating Shire operations in Sweden, highlights how Sweden’s innovation potential could pave the way for a value-based healthcare system, and how solutions and learnings from the Swedish affiliate…

Thailand Peter Streibl, general manager of Takeda Thailand, highlights the importance of emerging markets for Takeda globally, as well as the 50–year long commitment of Takeda to Thailand and Thai patients. Streibl further discusses how the Takeda Thailand team has worked to bring crucial innovative products and solutions in various therapeutic…

Spain Stefanie Granado, director general of Takeda Iberia recounts the opportunities available for Takeda in Spain following its acquisition of Shire. She also discusses Takeda’s local acquisition of TiGenix, handing Takeda stem cell production capabilities, and how this makes Spain a key market and hub for the company.   We continue…

Diversity Annually, PharmaBoardroom conducts hundreds of interviews with global CEO’s, country managers and industry leaders in the pharma industry. While we have crossed paths with many inspiring females in these positions, out of the top 50 pharma companies, only 3 are headed by women. That is a mere 6% — this…

France Marc Oczachowski, CEO of EDAP TMS, a French medtech and global leader in therapeutic ultrasound, elaborates on the history of the company while discussing their newest innovation for the noninvasive treatment of prostate cancer. Oczachowski also offers insights on the experiences of a local innovator moving from scale-up to internationalization…